MBX Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MBX Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.95 |
| 52 Week High | US$26.08 |
| 52 Week Low | US$20.29 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 1.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| MBX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 6.2% | -2.7% | 0.9% |
| 1Y | n/a | 21.0% | 32.3% |
Return vs Industry: Insufficient data to determine how MBX performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MBX performed against the US Market.
Price Volatility
| MBX volatility | |
|---|---|
| MBX Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MBX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MBX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 36 | Peter Hawryluk | mbxbio.com |
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.
MBX Biosciences, Inc. Fundamentals Summary
| MBX fundamental statistics | |
|---|---|
| Market cap | US$799.54m |
| Earnings (TTM) | -US$47.20m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-16.9x
P/E RatioIs MBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$47.20m |
| Earnings | -US$47.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.41 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MBX perform over the long term?
See historical performance and comparison